What tirzepatide costs at the 2.5 mg dose (the starting dose) — compounded flat pricing vs brand-name self-pay tiers.
2.5 mg is the standard starting dose. Most people stay here for about four weeks to let the body adjust before stepping up; it's a titration dose, not a maintenance dose. Compounded flat-rate pricing is identical at this dose; brand-name self-pay differs.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| NexLife Editor's pick | Compounded, flat | $186/mo* | Not FDA-approved |
| Zepbound® LillyDirect (2.5 mg, within 45-day window) | Brand vial | $299/mo | FDA-approved |
| Zepbound® standard self-pay (2.5 mg, window missed) | Brand vial | $349/mo | FDA-approved |
| Brand retail (any dose) | Brand pen | ~$1,086/mo | FDA-approved |
Verified July 2026. At 2.5 mg, compounded flat pricing stays at $186 while brand self-pay is $299–$349. See the full price-by-dose guide.
2.5 mg is the standard starting dose. Most people stay here for about four weeks to let the body adjust before stepping up; it's a titration dose, not a maintenance dose. Your clinician sets the titration schedule based on tolerance and response; side effects (mostly mild GI symptoms) are usually most noticeable when stepping up to a new dose. Compounded tirzepatide is not FDA-approved, and eligibility is determined by a licensed clinician. See safety & eligibility.
Compounded flat-rate pricing is $186/month at 2.5 mg; brand-name Zepbound self-pay is about $299/month within LillyDirect's 45-day window (up to $349 otherwise). Compounded is not FDA-approved. See NexLife pricing
Maintenance doses are typically higher (often 10–15 mg) and chosen by your clinician after titration. Your schedule is individualized.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.